[1] Molitch M E.Diagnosis and Treatment of Pituitary Adenomas: A Review[J]. Jama, 2017, 317(5):516-524. [2] Donoho D A, Bose N, Zada G, et al.Management of aggressive growth hormone secreting pituitary adenomas[J]. Pituitary, 2017, 20(1):169-178. [3] Ben-Shlomo A, Liu N A, Melmed S.Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas[J]. Pituitary, 2017, 20(1):93-99. [4] 张慧. RAF/MEK/ERK信号通路与垂体瘤发生的关系[J]. 国际神经病学神经外科学杂志, 2012, 39(6):573-576. [5] Vlotides G, Siegel E, Donangelo I, et al.Rat prolactinomas cell growth regulation by epidermal growth factor receptor ligands[J]. Cancer Res, 2008, 68(15):6377-6386. [6] Lodi A, Woods S M, Ronen S M.Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast but not in prostate cancer cells[J]. Nmr in Biomedicine, 2013, 26(3):299-306. [7] Meloche S, Pouyssegur J.The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition[J]. Oncogene, 2007, 26(22):3227. [8] Elsum I A, Martin C, Humbert P O. Scribble regulates an EMT polarity pathway through modulation of MAPK-ERK signaling to mediate junction formation[J]. J Cell Sci, 2013, 126(Pt 17):3990-3999. [9] Lania A, Filopanti M, Corbetta S, et al.Effects of hypothalamic neuropeptides on extracellular signal-regulated kinase (ERK1 and ERK2) cascade in human tumoral pituitary cells[J]. J Clin Endocrinol Metab, 2003, 88(4):1692-1696. [10] Gao H, Wang F, Lan X, et al.Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas[J]. Bmc Cancer, 2015, 15(1):272. [11] Han C K, Tien Y C, Hsieh J Y, et al.Attenuation of the LPS induced, ERK mediated upregulation of fibrosis related factors FGF 2, uPA, MMP 2, and MMP 9 by Carthamus tinctorius L in cardio-myoblasts[J]. Environmental Toxicology, 2017, 32(3):754-763. [12] 谢雨潇, 廖锐, 潘龙,等. 肝星状细胞条件培养基激活ERK1/2通路诱导肝癌细胞增殖及上皮间质转化[J]. 细胞与分子免疫学杂志, 2017, 33(2):210-214. [13] Chang F, Steelman L S, Shelton J G, et al.Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review)[J]. International Journal of Oncology, 2003, 22(3):469-480. [14] 王嵘, 史继新, 蒋健,等. 人垂体腺瘤中的细胞凋亡[J]. 中华神经外科杂志, 2005, 21(3):146-148. |